Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Arthritis
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The study aims to evaluate the safety and clinical effect of daily oral treatment with
laquinimod capsules (0.5mg /day and 1mg /day) in active lupus arthritis patients. Laquinimod
is a novel immunomodulating drug which is currently in advanced stages of development by Teva
Pharmaceuticals Ltd. For Multiple Sclerosis.
Phase:
Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries